2-Methoxyestradiol
- Generic Name
- 2-Methoxyestradiol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H26O3
- CAS Number
- 362-07-2
- Unique Ingredient Identifier
- 6I2QW73SR5
- Background
2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.
- Indication
For the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2009-02-26
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00592579
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00028821
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00030095
- Locations
- 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.